{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit was not estimable due to few participants with events","groupId":"OG000","lowerLimit":"2.3","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time, in months, from the date of first drug administration to the date of death (of any cause) or last patient contact (in this case, survival was to be censored on that date).","dispersionType":"95% Confidence Interval","groups":[{"description":"Plitidepsin was to be administered as a 3-hour (h) intravenous (i.v.) infusion at a dose of 5 mg/m2, on Day (D) 1 and 15, every four weeks (q4wk); BTZ was to be administered as a subcutaneous (s.c.) injection at a dose of 1.3 mg/m2 on D1, 4, 8 and 11, q4wk and DXM was to be taken orally at a dose of 40 mg/day on D1, 8, 15 and 22, q4wk. A cycle was defined as 28 days, plus any additional days required for dosing delays due to any reason. Treatment cycles were repeated q4wk.","id":"OG000","title":"Experimental"}],"paramType":"MEDIAN","populationDescription":"1 died without any valid tumor assessment done\n\n1 discontinued treatment-related AEs","reportingStatus":"POSTED","timeFrame":"From the date of first drug administration to the date of death (of any cause) or last patient contact, up to 100 weeks","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}